{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:22:42Z","timestamp":1791591762854,"version":"4.3.4"},"reference-count":236,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01769-x","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:35:11Z","timestamp":1761892511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["WT1 gene: a potential therapeutic target for multiple cancer treatment strategies"],"prefix":"10.1007","volume":"25","author":[{"given":"Tetsuyuki","family":"Hirahata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeshan","family":"Ul Quraish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afraz","family":"Ul Quraish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahan","family":"Ul Quraish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reezan","family":"Ul Quraish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"16","key":"1769_CR1","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1002\/cncr.33587","volume":"127","author":"F Bray","year":"2021","unstructured":"Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029\u201330. https:\/\/doi.org\/10.1002\/cncr.33587.","journal-title":"Cancer"},{"issue":"3","key":"1769_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1769_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"1769_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.colsurfb.2014.12.041","volume":"126","author":"M Estanqueiro","year":"2015","unstructured":"Estanqueiro M, Amaral MH, Concei\u00e7\u00e3o J, Sousa Lobo JM. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B Biointerfaces. 2015;126:631\u201348. https:\/\/doi.org\/10.1016\/j.colsurfb.2014.12.041.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"1769_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s43046-021-00088-y","volume":"33","author":"I Diori Karidio","year":"2021","unstructured":"Diori Karidio I, Sanlier SH. Reviewing cancer\u2019s biology: an eclectic approach. J Egypt Natl Canc Inst. 2021;33(1):32. https:\/\/doi.org\/10.1186\/s43046-021-00088-y.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"9","key":"1769_CR6","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.3390\/ijms23094723","volume":"23","author":"LV Loftus","year":"2022","unstructured":"Loftus LV, Amend SR, Pienta KJ. Interplay between cell death and cell proliferation reveals new strategies for cancer therapy. Int J Mol Sci. 2022;23(9):4723. https:\/\/doi.org\/10.3390\/ijms23094723.","journal-title":"Int J Mol Sci"},{"key":"1769_CR7","doi-asserted-by":"publisher","first-page":"117693512211507","DOI":"10.1177\/11769351221150772","volume":"22","author":"RU Quraish","year":"2023","unstructured":"Quraish RU, Hirahata T, Quraish AU, Ul Quraish S. An overview: genetic tumor markers for early detection and current gene therapy strategies. Cancer Inform. 2023;22:11769351221150772. https:\/\/doi.org\/10.1177\/11769351221150772.","journal-title":"Cancer Inform"},{"issue":"2","key":"1769_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.molcel.2010.01.010","volume":"37","author":"A Essafi","year":"2010","unstructured":"Essafi A, Hastie ND. WT1 the oncogene: a tale of death and HtrA. Mol Cell. 2010;37(2):153\u20135. https:\/\/doi.org\/10.1016\/j.molcel.2010.01.010.","journal-title":"Mol Cell"},{"issue":"11","key":"1769_CR9","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.21873\/anticanres.14622","volume":"40","author":"EN Kontomanolis","year":"2020","unstructured":"Kontomanolis EN, Koutras A, Syllaios A, Schizas D, Mastoraki A, Garmpis N, et al. Role of oncogenes and tumorsuppressor genes in carcinogenesis: a review. Anticancer Res. 2020;40(11):6009\u201315. https:\/\/doi.org\/10.21873\/anticanres.14622.","journal-title":"Anticancer Res"},{"issue":"6","key":"1769_CR10","doi-asserted-by":"publisher","first-page":"e582","DOI":"10.1002\/mco2.582","volume":"5","author":"TC Dakal","year":"2024","unstructured":"Dakal TC, Dhabhai B, Pant A, Moar K, Chaudhary K, Yadav V, et al. Oncogenes and tumor suppressor genes: functions and roles in cancers. MedComm. 2024;5(6):e582. https:\/\/doi.org\/10.1002\/mco2.582.","journal-title":"MedComm."},{"issue":"7","key":"1769_CR11","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/0092-8674(90)90690-g","volume":"61","author":"DA Haber","year":"1990","unstructured":"Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms\u2019 tumor. Cell. 1990;61(7):1257\u201369. https:\/\/doi.org\/10.1016\/0092-8674(90)90690-g.","journal-title":"Cell"},{"issue":"4","key":"1769_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41581-019-0112-0","volume":"15","author":"TD Treger","year":"2019","unstructured":"Treger TD, Chowdhury T, Pritchard-Jones K, Behjati S. The genetic changes of Wilms tumour. Nat Rev Nephrol. 2019;15(4):240\u201351. https:\/\/doi.org\/10.1038\/s41581-019-0112-0.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"1769_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/gcc.20553","volume":"47","author":"EC Ruteshouser","year":"2008","unstructured":"Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer. 2008;47(6):461\u201370. https:\/\/doi.org\/10.1002\/gcc.20553.","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"1769_CR14","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.31557\/APJCP.2024.25.10.3463","volume":"25","author":"GRJ Anitha","year":"2024","unstructured":"Anitha GRJ, Chandraprabha VR, Padmakumar D, Sreelatha MM, Padmakumar A, Gopinath P, et al. Exploring the prevalence and prognostic impact of Wilms tumor 1 exon 7 mutation status with combinations of FLT3-ITD and NPM1 mutations as potential molecular biomarkers in acute myeloid leukemia patients with normal cytogenetics. Asian Pac J Cancer Prev. 2024;25(10):3463\u201370. https:\/\/doi.org\/10.31557\/APJCP.2024.25.10.3463.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"1769_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrc3002","volume":"11","author":"V Huff","year":"2011","unstructured":"Huff V. Wilms\u2019 tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer. 2011;11(2):111\u201321. https:\/\/doi.org\/10.1038\/nrc3002.","journal-title":"Nat Rev Cancer"},{"key":"1769_CR16","doi-asserted-by":"publisher","first-page":"1093945","DOI":"10.1155\/2022\/1093945","volume":"2022","author":"YJ Jing","year":"2022","unstructured":"Jing YJ, Lin LC, Chen LL, et al. WT1 inhibits human renal carcinoma cell proliferation and induces G2\/M arrest by upregulating IL-24 expression. Biomed Res Int. 2022;2022:1093945. https:\/\/doi.org\/10.1155\/2022\/1093945.","journal-title":"Biomed Res Int"},{"issue":"6","key":"1769_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3324\/haematol.2015.141796","volume":"101","author":"R Rampal","year":"2016","unstructured":"Rampal R, Figueroa ME. Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia. Haematologica. 2016;101(6):672\u20139. https:\/\/doi.org\/10.3324\/haematol.2015.141796.","journal-title":"Haematologica"},{"key":"1769_CR18","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41416-018-0317-1","volume":"119","author":"RJ McGregor","year":"2018","unstructured":"McGregor RJ, Chau Y, Kendall TJ, Artibani M, Hastie N, Hadoke PWF. WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer. Br J Cancer. 2018;119:1508\u201317. https:\/\/doi.org\/10.1038\/s41416-018-0317-1.","journal-title":"Br J Cancer"},{"issue":"5","key":"1769_CR19","first-page":"2331","volume":"34","author":"Z Liu","year":"2014","unstructured":"Liu Z, Yamanouchi K, Ohtao T, et al. High levels of Wilms\u2019 tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer. Anticancer Res. 2014;34(5):2331\u201340.","journal-title":"Anticancer Res"},{"issue":"4","key":"1769_CR20","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3390\/biomedicines10040912","volume":"10","author":"D Novacescu","year":"2022","unstructured":"Novacescu D, Cut TG, Cumpanas AA, Latcu CS, Bardan R, Ferician O, et al. Evaluating established roles, future perspectives and methodological heterogeneity for Wilms\u2019 Tumor 1 (WT1) antigen detection in adult renal cell carcinoma, using a novel N-terminus targeted antibody (clone WT49). Biomedicines. 2022;10(4):912. https:\/\/doi.org\/10.3390\/biomedicines10040912.","journal-title":"Biomedicines."},{"issue":"4","key":"1769_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3892\/ol.2012.578","volume":"3","author":"P Zapata-Benavides","year":"2012","unstructured":"Zapata-Benavides P, Manilla-Mu\u00f1oz E, Zamora-Avila DE, et al. WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells. Oncol Lett. 2012;3(4):751\u20135. https:\/\/doi.org\/10.3892\/ol.2012.578.","journal-title":"Oncol Lett"},{"issue":"1","key":"1769_CR22","first-page":"61","volume":"34","author":"N Kijima","year":"2014","unstructured":"Kijima N, Hosen N, Kagawa N, Kinoshita M, Oji Y, et al. Wilms\u2019 tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis. Anticancer Res. 2014;34(1):61\u20137.","journal-title":"Anticancer Res"},{"key":"1769_CR23","doi-asserted-by":"publisher","unstructured":"Kijima N, Hashimoto N, Chiba Y, Fujimoto Y, Sugiyama H, Yoshimine T. Functional roles of Wilms\u2019 Tumor 1 (WT1) in malignant brain tumors. In: van den Heuvel-Eibrink MM, ed. Wilms Tumor. Brisbane (AU): Codon Publications; 2016. Chapter 15. https:\/\/doi.org\/10.15586\/codon.wt.2016.ch15.","DOI":"10.15586\/codon.wt.2016.ch15"},{"issue":"6","key":"1769_CR24","doi-asserted-by":"publisher","first-page":"101582","DOI":"10.1016\/j.xcrm.2024.101582","volume":"5","author":"C Henon","year":"2024","unstructured":"Henon C, Vibert J, Eychenne T, Colmet-Daage L, Ngo C, Garrido M, et al. Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs. Cell Rep Med. 2024;5(6):101582. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101582.","journal-title":"Cell Rep Med"},{"issue":"5","key":"1769_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/jjco\/hyp194","volume":"40","author":"H Sugiyama","year":"2010","unstructured":"Sugiyama H. WT1 (Wilms\u2019 Tumor Gene 1): biology and Cancer Immunotherapy. Jpn J Clin Oncol. 2010;40(5):377\u201387. https:\/\/doi.org\/10.1093\/jjco\/hyp194.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"1769_CR26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/ki.2015.198","volume":"88","author":"L Dong","year":"2015","unstructured":"Dong L, Pietsch S, Englert C. Towards an understanding of kidney diseases associated with WT1 mutations. Kidney Int. 2015;88(4):684\u201390. https:\/\/doi.org\/10.1038\/ki.2015.198.","journal-title":"Kidney Int"},{"issue":"5","key":"1769_CR27","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jmb.2007.07.017","volume":"372","author":"R Stoll","year":"2007","unstructured":"Stoll R, Lee BM, Debler EW, Laity JH, Wilson IA, Dyson HJ, et al. Structure of the Wilms tumor suppressor protein zinc finger domain bound to DNA. J Mol Biol. 2007;372(5):1227\u201345.","journal-title":"J Mol Biol"},{"issue":"2","key":"1769_CR28","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3324\/haematol.2016.149815","volume":"102","author":"T Ullmark","year":"2017","unstructured":"Ullmark T, J\u00e4rvstr\u00e5t L, Sand\u00e9n C, Montano G, Jernmark-Nilsson H, Lilljebj\u00f6rn H, et al. Distinct global binding patterns of the Wilms tumor gene 1 (WT1) -KTS and +KTS isoforms in leukemic cells. Haematologica. 2017;102(2):336\u201345. https:\/\/doi.org\/10.3324\/haematol.2016.149815.","journal-title":"Haematologica"},{"key":"1769_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgx108","author":"KY Lee","year":"2017","unstructured":"Lee KY, Jeon YJ, Kim HG, Ryu J, Lim DY, Jung SK, et al. The CUG-translated WT1, not AUG-WT1, is an oncogene. Carcinogenesis. 2017. https:\/\/doi.org\/10.1093\/carcin\/bgx108.","journal-title":"Carcinogenesis"},{"key":"1769_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00467-013-2673-7","volume":"29","author":"DD Ozdemir","year":"2014","unstructured":"Ozdemir DD, Hohenstein P. WT1 in the kidney\u2014a tale in mouse models. Pediatr Nephrol. 2014;29:687\u201393. https:\/\/doi.org\/10.1007\/s00467-013-2673-7.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"1769_CR31","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2215\/CJN.05670809","volume":"5","author":"E Benetti","year":"2010","unstructured":"Benetti E, Caridi G, Malaventura C, Dagnino M, Leonardi E, Artifoni L, et al. A novel WT1 gene mutation in a three-generation family with progressive isolated focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5(4):698\u2013702. https:\/\/doi.org\/10.2215\/CJN.05670809.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1769_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ejh.13010","volume":"100","author":"T Ullmark","year":"2018","unstructured":"Ullmark T, Montano G, Gullberg U. DNA and RNA binding by the Wilms\u2019 tumour gene 1 (WT1) protein +KTS and -KTS isoforms\u2014from initial observations to recent global genomic analyses. Eur J Haematol. 2018;100(3):229\u201340. https:\/\/doi.org\/10.1111\/ejh.13010.","journal-title":"Eur J Haematol"},{"issue":"7","key":"1769_CR33","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1158\/1541-7786.MCR-10-0033","volume":"8","author":"J Wells","year":"2010","unstructured":"Wells J, Rivera MN, Kim WJ, Starbuck K, Haber DA. The predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes. Mol Cancer Res. 2010;8(7):975\u201385. https:\/\/doi.org\/10.1158\/1541-7786.MCR-10-0033.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"1769_CR34","first-page":"3637","volume":"30","author":"L Wang","year":"2010","unstructured":"Wang L, Zhang X, Wang ZY. The Wilms\u2019 tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance. Anticancer Res. 2010;30(9):3637\u201342.","journal-title":"Anticancer Res"},{"issue":"4","key":"1769_CR35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1139\/o08-075","volume":"86","author":"C Yang","year":"2008","unstructured":"Yang C, Romaniuk PJ. The ratio of +\/\u2212KTS splice variants of the Wilms\u2019 tumour suppressor protein WT1 mRNA is determined by an intronic enhancer. Biochem Cell Biol. 2008;86(4):312\u201321. https:\/\/doi.org\/10.1139\/o08-075.","journal-title":"Biochem Cell Biol"},{"issue":"1","key":"1769_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.acthis.2013.05.003","volume":"116","author":"R Parenti","year":"2014","unstructured":"Parenti R, Puzzo L, Vecchio GM, Gravina L, Salvatorelli L, Musumeci G, et al. Immunolocalization of Wilms\u2032 tumor protein (WT1) in developing human peripheral sympathetic and gastroenteric nervous system. Acta Histochem. 2014;116(1):48\u201354. https:\/\/doi.org\/10.1016\/j.acthis.2013.05.003.","journal-title":"Acta Histochem"},{"issue":"1","key":"1769_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.acthis.2012.04.006","volume":"115","author":"R Parenti","year":"2013","unstructured":"Parenti R, Perris R, Vecchio GM, Salvatorelli L, Torrisi A, Gravina L, et al. Immunohistochemical expression of Wilms\u2019 tumor protein (WT1) in developing human epithelial and mesenchymal tissues. Acta Histochem. 2013;115(1):70\u20135. https:\/\/doi.org\/10.1016\/j.acthis.2012.04.006.","journal-title":"Acta Histochem"},{"issue":"4\u20135","key":"1769_CR38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.acthis.2015.03.009","volume":"117","author":"R Parenti","year":"2015","unstructured":"Parenti R, Salvatorelli L, Musumeci G, Parenti C, Giorlandino A, Motta F, et al. Wilms\u2019 tumor 1 (WT1) protein expression in human developing tissues. Acta Histochem. 2015;117(4\u20135):386\u201396. https:\/\/doi.org\/10.1016\/j.acthis.2015.03.009.","journal-title":"Acta Histochem"},{"issue":"2","key":"1769_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/path.2977","volume":"226","author":"E Miller-Hodges","year":"2012","unstructured":"Miller-Hodges E, Hohenstein P. WT1 in disease: shifting the epithelial-mesenchymal balance. J Pathol. 2012;226(2):229\u201340. https:\/\/doi.org\/10.1002\/path.2977.","journal-title":"J Pathol"},{"issue":"22","key":"1769_CR40","doi-asserted-by":"publisher","first-page":"16278","DOI":"10.1074\/jbc.M700215200","volume":"282","author":"MS Kim","year":"2007","unstructured":"Kim MS, Hancock AL, Harper JC, Park JY, Poy G, Perantoni AO, et al. Identification of novel Wilms\u2019 tumor suppressor gene target genes implicated in kidney development. J Biol Chem. 2007;282(22):16278\u201387. https:\/\/doi.org\/10.1074\/jbc.M700215200.","journal-title":"J Biol Chem"},{"issue":"27","key":"1769_CR41","doi-asserted-by":"publisher","first-page":"11154","DOI":"10.1073\/pnas.0901591106","volume":"106","author":"MK Kim","year":"2009","unstructured":"Kim MK, McGarry TJ, O Broin P, Flatow JM, Golden AA, Licht JD. An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. Proc Natl Acad Sci USA. 2009;106(27):11154\u20139. https:\/\/doi.org\/10.1073\/pnas.0901591106.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1769_CR42","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.gde.2005.08.004","volume":"15","author":"SGE Roberts","year":"2005","unstructured":"Roberts SGE. Transcriptional regulation by WT1 in development. Curr Opin Genet Dev. 2005;15(5):542\u20137. https:\/\/doi.org\/10.1016\/j.gde.2005.08.004.","journal-title":"Curr Opin Genet Dev"},{"issue":"3","key":"1769_CR43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.devcel.2011.07.014","volume":"21","author":"A Essafi","year":"2011","unstructured":"Essafi A, Webb A, Berry RL, Slight J, Burn SF, Spraggon L, et al. A WT1-controlled chromatin switching mechanism underpins tissue-specific Wnt4 activation and repression. Dev Cell. 2011;21(3):559\u201374. https:\/\/doi.org\/10.1016\/j.devcel.2011.07.014.","journal-title":"Dev Cell"},{"issue":"1","key":"1769_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1042\/BJ20131587","volume":"461","author":"E Toska","year":"2014","unstructured":"Toska E, Roberts SGE. Mechanisms of transcriptional regulation by WT1 (Wilms\u2019 tumour 1). Biochem J. 2014;461(1):15\u201332. https:\/\/doi.org\/10.1042\/BJ20131587.","journal-title":"Biochem J"},{"issue":"47","key":"1769_CR45","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.1038\/sj.onc.1203046","volume":"18","author":"LM McKay","year":"1999","unstructured":"McKay LM, Carpenter B, Roberts SGE. Regulation of the Wilms\u2019 tumour suppressor protein transcriptional activation domain. Oncogene. 1999;18(47):6546\u201354. https:\/\/doi.org\/10.1038\/sj.onc.1203046.","journal-title":"Oncogene"},{"issue":"2","key":"1769_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0378-1119(01)00593-5","volume":"273","author":"V Scharnhorst","year":"2001","unstructured":"Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene. 2001;273(2):141\u201361. https:\/\/doi.org\/10.1016\/S0378-1119(01)00593-5.","journal-title":"Gene"},{"issue":"14","key":"1769_CR47","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1093\/nar\/27.14.2889","volume":"27","author":"TH Lee","year":"1999","unstructured":"Lee TH, Moffett P, Pelletier J. The Wilms\u2019 tumor suppressor gene (WT1) product represses different functional classes of transcriptional activation domains. Nucleic Acids Res. 1999;27(14):2889\u201397. https:\/\/doi.org\/10.1093\/nar\/27.14.2889.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"1769_CR48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1128\/MCB.24.2.537-549.2004","volume":"24","author":"B Carpenter","year":"2004","unstructured":"Carpenter B, Hill KJ, Charalambous M, Wagner KJ, Lahiri D, James DI, et al. BASP1 is a transcriptional cosuppressor for the Wilms\u2019 tumor suppressor protein WT1. Mol Cell Biol. 2004;24(2):537\u201349. https:\/\/doi.org\/10.1128\/MCB.24.2.537-549.2004.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"1769_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/BF02981935","volume":"73","author":"H Sugiyama","year":"2001","unstructured":"Sugiyama H. Wilms\u2019 tumor gene WT1: its oncogenic function and clinical application. Int J Hematol. 2001;73(2):177\u201387. https:\/\/doi.org\/10.1007\/BF02981935.","journal-title":"Int J Hematol"},{"key":"1769_CR50","doi-asserted-by":"publisher","first-page":"100143","DOI":"10.1016\/j.endmts.2023.100143","volume":"13","author":"MT Ferrari","year":"2023","unstructured":"Ferrari MT, Elias FM, Gomes NL, Batista RL, Faria JA Jr, Nishi MY. WT1: A single gene associated with multiple and severe phenotypes. Endocrine and Metabolic Science. 2023;13:100143. https:\/\/doi.org\/10.1016\/j.endmts.2023.100143.","journal-title":"Endocrine and Metabolic Science."},{"issue":"16","key":"1769_CR51","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1242\/dev.153163","volume":"144","author":"ND Hastie","year":"2017","unstructured":"Hastie ND. Wilms\u2019 tumour 1 (WT1) in development, homeostasis and disease. Development. 2017;144(16):2862\u201372. https:\/\/doi.org\/10.1242\/dev.153163.","journal-title":"Development"},{"issue":"24","key":"1769_CR52","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3390\/cells13242078","volume":"13","author":"S Del D\u00edaz Moral","year":"2024","unstructured":"Del D\u00edaz Moral S, Wagner N, Wagner KD. The Wilms\u2019 tumor suppressor WT1 in cardiomyocytes: implications for cardiac homeostasis and repair. Cells. 2024;13(24):2078. https:\/\/doi.org\/10.3390\/cells13242078.","journal-title":"Cells"},{"key":"1769_CR53","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s41417-024-00795-3","volume":"31","author":"J Quenneville","year":"2024","unstructured":"Quenneville J, Feghaly A, Tual M, et al. Long-term severe hypoxia adaptation induces non-canonical EMT and a novel Wilms tumor 1 (WT1) isoform. Cancer Gene Ther. 2024;31:1237\u201350. https:\/\/doi.org\/10.1038\/s41417-024-00795-3.","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"1769_CR54","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/j.stemcr.2021.07.023","volume":"16","author":"V Waehle","year":"2021","unstructured":"Waehle V, Ungricht R, Hoppe PS, Betschinger J. The tumor suppressor WT1 drives progenitor cell progression and epithelialization to prevent Wilms tumorigenesis in human kidney organoids. Stem Cell Reports. 2021;16(9):2107\u201317. https:\/\/doi.org\/10.1016\/j.stemcr.2021.07.023.","journal-title":"Stem Cell Reports"},{"issue":"3","key":"1769_CR55","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0092-8674(95)90392-5","volume":"81","author":"SH Larsson","year":"1995","unstructured":"Larsson SH, Charlieu JP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, et al. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell. 1995;81(3):391\u2013401. https:\/\/doi.org\/10.1016\/0092-8674(95)90392-5.","journal-title":"Cell"},{"issue":"7","key":"1769_CR56","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/onc.2009.444","volume":"29","author":"T Dudnakova","year":"2010","unstructured":"Dudnakova T, Spraggon L, Slight J, Hastie N. Actin: a novel interaction partner of WT1 influencing its cell dynamic properties. Oncogene. 2010;29(7):1085\u201392. https:\/\/doi.org\/10.1038\/onc.2009.444.","journal-title":"Oncogene"},{"issue":"4","key":"1769_CR57","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/hmg\/ddh040","volume":"13","author":"M Niksic","year":"2004","unstructured":"Niksic M, Slight J, Sanford J, Caceres JF, Hastie ND. The Wilms\u2019 tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. Hum Mol Genet. 2004;13(4):463\u201371. https:\/\/doi.org\/10.1093\/hmg\/ddh040.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"1769_CR58","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ccell.2015.01.002","volume":"27","author":"J Wegert","year":"2015","unstructured":"Wegert J, Ishaque N, Vardapour R, Ge\u00f6rg C, Gu Z, Bieg M, et al. Mutations in the SIX1\/2 pathway and the DROSHA\/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell. 2015;27(2):298\u2013311. https:\/\/doi.org\/10.1016\/j.ccell.2015.01.002.","journal-title":"Cancer Cell"},{"issue":"1","key":"1769_CR59","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11033-024-09450-4","volume":"51","author":"H Ben Haj Othmen","year":"2024","unstructured":"Ben Haj Othmen H, Othman H, Khamessi O, Bettaieb I, Gara S, Kharrat M. Overexpression of WT1 in all molecular subtypes of breast cancer and its impact on survival: exploring oncogenic and tumor suppressor roles of distinct WT1 isoforms. Mol Biol Rep. 2024;51(1):544. https:\/\/doi.org\/10.1007\/s11033-024-09450-4.","journal-title":"Mol Biol Rep"},{"issue":"Spec No 2","key":"1769_CR60","doi-asserted-by":"publisher","first-page":"R196","DOI":"10.1093\/hmg\/ddl196","volume":"15","author":"P Hohenstein","year":"2006","unstructured":"Hohenstein P, Hastie ND. The many facets of the Wilms\u2019 tumour gene, WT1. Hum Mol Genet. 2006;15(Spec No 2):R196\u2013201. https:\/\/doi.org\/10.1093\/hmg\/ddl196.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"1769_CR61","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.tig.2012.04.004","volume":"28","author":"YY Chau","year":"2012","unstructured":"Chau YY, Hastie ND. The role of WT1 in regulating mesenchyme in cancer, development, and tissue homeostasis. Trends Genet. 2012;28(10):515\u201324. https:\/\/doi.org\/10.1016\/j.tig.2012.04.004.","journal-title":"Trends Genet"},{"issue":"16","key":"1769_CR62","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1080\/15384101.2021.1951938","volume":"20","author":"Y Yao","year":"2021","unstructured":"Yao Y, Chai X, Gong C, Zou L. WT1 inhibits AML cell proliferation in a p53-dependent manner. Cell Cycle. 2021;20(16):1552\u201360. https:\/\/doi.org\/10.1080\/15384101.2021.1951938.","journal-title":"Cell Cycle"},{"issue":"5","key":"1769_CR63","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/sj.leu.2404624","volume":"21","author":"L Yang","year":"2007","unstructured":"Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007;21(5):868\u201376. https:\/\/doi.org\/10.1038\/sj.leu.2404624.","journal-title":"Leukemia"},{"issue":"30","key":"1769_CR64","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1038\/sj.onc.1209455","volume":"25","author":"K Ito","year":"2006","unstructured":"Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T, Asada M, et al. Antiapoptotic function of 17AA(+)WT1 (Wilms\u2019 tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene. 2006;25(30):4217\u201329. https:\/\/doi.org\/10.1038\/sj.onc.1209455.","journal-title":"Oncogene"},{"issue":"39","key":"1769_CR65","doi-asserted-by":"publisher","first-page":"32875","DOI":"10.1074\/jbc.C112.366559","volume":"287","author":"H Bansal","year":"2012","unstructured":"Bansal H, Seifert T, Bachier C, Rao M, Tomlinson G, Iyer SP, et al. The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL by regulating the antiapoptotic protein Bcl-xL. J Biol Chem. 2012;287(39):32875\u201380. https:\/\/doi.org\/10.1074\/jbc.C112.366559.","journal-title":"J Biol Chem"},{"issue":"12","key":"1769_CR66","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1182\/blood-2005-10-4025","volume":"107","author":"LA Simpson","year":"2006","unstructured":"Simpson LA, Burwell EA, Thompson KA, Shahnaz S, Chen AR, Loeb DM. The antiapoptotic gene A1\/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood. 2006;107(12):4695\u2013702. https:\/\/doi.org\/10.1182\/blood-2005-10-4025.","journal-title":"Blood"},{"key":"1769_CR67","doi-asserted-by":"publisher","first-page":"102237","DOI":"10.1016\/j.tranon.2024.102237","volume":"52","author":"N Qing","year":"2025","unstructured":"Qing N, Lin Y, Zeng J, Zhang Y, Liu R. Multifaceted functions of the Wilms tumor 1 protein: from its expression in various malignancies to targeted therapy. Transl Oncol. 2025;52:102237. https:\/\/doi.org\/10.1016\/j.tranon.2024.102237.","journal-title":"Transl Oncol"},{"issue":"1","key":"1769_CR68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13045-025-01661-x","volume":"18","author":"ZN Berneman","year":"2025","unstructured":"Berneman ZN, De Laere M, Germonpr\u00e9 P, et al. WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome. J Hematol Oncol. 2025;18(1):9. https:\/\/doi.org\/10.1186\/s13045-025-01661-x.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"1769_CR69","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2017-08-802926","volume":"132","author":"Y Akahori","year":"2018","unstructured":"Akahori Y, Wang L, Yoneyama M, et al. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood. 2018;132(11):1134\u201345. https:\/\/doi.org\/10.1182\/blood-2017-08-802926.","journal-title":"Blood"},{"issue":"8","key":"1769_CR70","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1101\/gad.12.8.1108","volume":"12","author":"S Maheswaran","year":"1998","unstructured":"Maheswaran S, Englert C, Zheng G, et al. Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70. Genes Dev. 1998;12(8):1108\u201320. https:\/\/doi.org\/10.1101\/gad.12.8.1108.","journal-title":"Genes Dev"},{"issue":"17","key":"1769_CR71","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1101\/gad.9.17.2143","volume":"9","author":"S Maheswaran","year":"1995","unstructured":"Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 1995;9(17):2143\u201356. https:\/\/doi.org\/10.1101\/gad.9.17.2143.","journal-title":"Genes Dev"},{"issue":"2","key":"1769_CR72","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3324\/haematol.2017.170431","volume":"103","author":"F Bordin","year":"2018","unstructured":"Bordin F, Piovan E, Masiero E, et al. WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. Haematologica. 2018;103(2):266\u201377. https:\/\/doi.org\/10.3324\/haematol.2017.170431.","journal-title":"Haematologica"},{"issue":"32","key":"1769_CR73","doi-asserted-by":"publisher","first-page":"33575","DOI":"10.1074\/jbc.M404787200","volume":"279","author":"P Stanhope-Baker","year":"2004","unstructured":"Stanhope-Baker P, Kessler PM, Li W, Agarwal ML, Williams BR. The Wilms tumor suppressor-1 target gene podocalyxin is transcriptionally repressed by p53. J Biol Chem. 2004;279(32):33575\u201385. https:\/\/doi.org\/10.1074\/jbc.M404787200.","journal-title":"J Biol Chem"},{"key":"1769_CR74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-94017-9211-0_2","volume":"85","author":"K Inoue","year":"2014","unstructured":"Inoue K, Fry EA. Alterations of p63 and p73 in human cancers. Subcell Biochem. 2014;85:17\u201340. https:\/\/doi.org\/10.1007\/978-94017-9211-0_2.","journal-title":"Subcell Biochem"},{"issue":"14","key":"1769_CR75","doi-asserted-by":"publisher","first-page":"10202","DOI":"10.1074\/jbc.275.14.10202","volume":"275","author":"V Scharnhorst","year":"2000","unstructured":"Scharnhorst V, Dekker P, van der Eb AJ, Jochemsen AG. Physical interaction between Wilms tumor 1 and p73 proteins modulates their functions. J Biol Chem. 2000;275(14):10202\u201311. https:\/\/doi.org\/10.1074\/jbc.275.14.10202.","journal-title":"J Biol Chem"},{"issue":"1","key":"1769_CR76","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12885-015-1356-0","volume":"15","author":"X Li","year":"2015","unstructured":"Li X, Ottosson S, Wang S, et al. Wilms\u2019 tumor gene 1 regulates p63 and promotes cell proliferation in squamous cell carcinoma of the head and neck. BMC Cancer. 2015;15(1):342. https:\/\/doi.org\/10.1186\/s12885-015-1356-0.","journal-title":"BMC Cancer"},{"key":"1769_CR77","doi-asserted-by":"publisher","unstructured":"Wu C, Yang J, Li R, Lin X, Wu J, Wu J. LncRNA WT1-AS\/miR-494\u20133p regulates cell proliferation, apoptosis, migration and invasion via PTEN\/PI3K\/AKT signaling pathway in non-small cell lung cancer. Onco Targets Ther. 2021;14: 891\u2013904. Published 2021 Feb 9. [Retracted in: Onco Targets Ther. 2024; 17:739\u2013740. https:\/\/doi.org\/10.2147\/OTT.S278233.","DOI":"10.2147\/OTT.S278233"},{"issue":"7","key":"1769_CR78","doi-asserted-by":"publisher","first-page":"136","DOI":"10.21037\/atm.2019.03.37","volume":"7","author":"W Chen","year":"2019","unstructured":"Chen W, Zhuang J, Gong L, Dai Y, Diao H. Investigating the dysfunctional pathogenesis of Wilms\u2019 tumor through a multidimensional integration strategy. Ann Transl Med. 2019;7(7):136. https:\/\/doi.org\/10.21037\/atm.2019.03.37.","journal-title":"Ann Transl Med"},{"key":"1769_CR79","doi-asserted-by":"publisher","unstructured":"Liu GL, Yang HJ, Liu B, Liu T. Effects of microRNA-19b on the proliferation, apoptosis, and migration of Wilms\u2019 tumor cells via the PTEN\/PI3K\/AKT signaling pathway. J Cell Biochem. 2017;118(10):3424\u20133434. [Retracted in: J Cell Biochem. 2021 Nov;122(Suppl 1):S55. https:\/\/doi.org\/10.1002\/jcb.25999.","DOI":"10.1002\/jcb.25999"},{"issue":"15","key":"1769_CR80","doi-asserted-by":"publisher","first-page":"e113565","DOI":"10.15252\/embj.2023113565","volume":"42","author":"SR Witus","year":"2023","unstructured":"Witus SR, Tuttle LM, Li W, et al. BRCA1\/BARD1 intrinsically disordered regions facilitate chromatin recruitment and ubiquitylation. EMBO J. 2023;42(15):e113565. https:\/\/doi.org\/10.15252\/embj.2023113565.","journal-title":"EMBO J"},{"issue":"1","key":"1769_CR81","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13073-025-01482-0","volume":"17","author":"J Wegert","year":"2025","unstructured":"Wegert J, Appenzeller S, Treger TD, et al. Distinct pathways for genetic and epigenetic predisposition in familial and bilateral Wilms tumor. Genome Med. 2025;17(1):49. https:\/\/doi.org\/10.1186\/s13073-025-01482-0.","journal-title":"Genome Med"},{"issue":"2","key":"1769_CR82","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1074\/jbc.M113.483255","volume":"289","author":"MI Rather","year":"2014","unstructured":"Rather MI, Swamy S, Gopinath KS, Kumar A. Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics. J Biol Chem. 2014;289(2):968\u201376. https:\/\/doi.org\/10.1074\/jbc.M113.483255.","journal-title":"J Biol Chem"},{"issue":"14","key":"1769_CR83","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1093\/emboj\/18.14.3990","volume":"18","author":"MW Mayo","year":"1999","unstructured":"Mayo MW, Wang CY, Drouin SS, et al. WT1 modulates apoptosis by transcriptionally upregulating the Bcl-2 protooncogene. EMBO J. 1999;18(14):3990\u20134003. https:\/\/doi.org\/10.1093\/emboj\/18.14.3990.","journal-title":"EMBO J"},{"issue":"18","key":"1769_CR84","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1158\/0008-5472.CAN-04-3657","volume":"65","author":"DJ Morrison","year":"2005","unstructured":"Morrison DJ, English MA, Licht JD. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl2 family member Bak. Cancer Res. 2005;65(18):8174\u201382. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-3657.","journal-title":"Cancer Res"},{"issue":"22","key":"1769_CR85","doi-asserted-by":"publisher","first-page":"19995","DOI":"10.1074\/jbc.M205865200","volume":"278","author":"SK Cheema","year":"2003","unstructured":"Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the Bcl-2 promoter. J Biol Chem. 2003;278(22):19995\u201320005. https:\/\/doi.org\/10.1074\/jbc.M205865200.","journal-title":"J Biol Chem"},{"issue":"7","key":"1769_CR86","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/15417786.MCR-08-0078","volume":"6","author":"DJ Morrison","year":"2008","unstructured":"Morrison DJ, Kim MK, Berkofsky-Fessler W, Licht JD. WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression. Mol Cancer Res. 2008;6(7):1225\u201331. https:\/\/doi.org\/10.1158\/15417786.MCR-08-0078.","journal-title":"Mol Cancer Res"},{"key":"1769_CR87","first-page":"3575","volume":"23","author":"TF Zhang","year":"2003","unstructured":"Zhang TF, Yu SQ, Guan LS, Wang ZY. Inhibition of breast cancer cell growth by the Wilms\u2019 tumor suppressor WT1 is associated with a destabilization of beta-catenin. Anticancer Res. 2003;23:3575\u201384.","journal-title":"Anticancer Res"},{"issue":"176","key":"1769_CR88","doi-asserted-by":"publisher","first-page":"176ra33","DOI":"10.1126\/scitranslmed.3005661","volume":"5","author":"T Dao","year":"2013","unstructured":"Dao T, Yan S, Veomett N, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med. 2013;5(176):176ra33. https:\/\/doi.org\/10.1126\/scitranslmed.3005661.","journal-title":"Sci Transl Med"},{"issue":"6","key":"1769_CR89","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/vaccines11061062","volume":"11","author":"E Manthopoulou","year":"2023","unstructured":"Manthopoulou E, Ramai D, Dhar J, et al. Cholangiocarcinoma in the era of immunotherapy. Vaccines (Basel). 2023;11(6):1062.","journal-title":"Vaccines (Basel)"},{"key":"1769_CR90","unstructured":"Green BL. A peptide vaccine targeting WT1 for cholangiocarcinoma. Cholangiocarcinoma Foundation 2024 Annual Conference. Presented April 17\u201319, 2024. Accessed 6 June 2024."},{"issue":"1","key":"1769_CR91","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1186\/s12885-023-11399-9","volume":"23","author":"X Li","year":"2023","unstructured":"Li X, An W, Pan H, et al. Wilms\u2019 tumour gene 1 (WT1) enhances non-small cell lung cancer malignancy and is inhibited by microRNA-498-5p. BMC Cancer. 2023;23(1):909. https:\/\/doi.org\/10.1186\/s12885-023-11399-9.","journal-title":"BMC Cancer"},{"issue":"1","key":"1769_CR92","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/CJI.0000000000000405","volume":"45","author":"S Nishida","year":"2022","unstructured":"Nishida S, Morimoto S, Oji Y, et al. Cellular and humoral immune responses induced by an HLA class I-restricted peptide cancer vaccine targeting WT1 are associated with favorable clinical outcomes in advanced ovarian cancer. J Immunother. 2022;45(1):56\u201366. https:\/\/doi.org\/10.1097\/CJI.0000000000000405.","journal-title":"J Immunother"},{"issue":"22","key":"1769_CR93","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1182\/blood.V128.22.3984.3984","volume":"128","author":"H Liu","year":"2016","unstructured":"Liu H, Zha Y, Malnassy G, Fulton N. WT1 peptide vaccine is able to induce WT1-specific immune response with TCR clonal enrichment to control minimal residual disease in patients with myeloid leukemia. Blood. 2016;128(22):3984. https:\/\/doi.org\/10.1182\/blood.V128.22.3984.3984.","journal-title":"Blood"},{"key":"1769_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-018-0093x","volume":"7","author":"H Liu","year":"2018","unstructured":"Liu H, Zha Y, Choudhury N, et al. WT1 peptide vaccine in Montanide, in contrast to poly ICLC, is able to induce WT1specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol. 2018;7:1. https:\/\/doi.org\/10.1186\/s40164-018-0093x.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1769_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-024-02539-x","volume":"29","author":"C Nagano","year":"2025","unstructured":"Nagano C, Nozu K. A review of the genetic background in complicated WT1-related disorders. Clin Exp Nephrol. 2025;29(1):1\u20139. https:\/\/doi.org\/10.1007\/s10157-024-02539-x.","journal-title":"Clin Exp Nephrol"},{"issue":"8","key":"1769_CR96","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1016\/j.ekir.2021.05.009","volume":"6","author":"C Nagano","year":"2021","unstructured":"Nagano C, Takaoka Y, Kamei K, et al. Genotype-phenotype correlation in WT1 exon 8 to 9 missense variants. Kidney Int Rep. 2021;6(8):2114\u201321. https:\/\/doi.org\/10.1016\/j.ekir.2021.05.009.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"1769_CR97","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/ki.2013.519","volume":"85","author":"BS Lipska","year":"2014","unstructured":"Lipska BS, et al. Genotype\u2013phenotype associations in WT1 glomerulopathy. Kidney Int. 2014;85(5):1169\u201378.","journal-title":"Kidney Int"},{"key":"1769_CR98","doi-asserted-by":"publisher","first-page":"1192021","DOI":"10.3389\/fped.2023.1192021","volume":"11","author":"H Chen","year":"2023","unstructured":"Chen H, Zhang M, Lin J, et al. Genotype-phenotype correlation of WT1 mutation-related nephropathy in Chinese children. Front Pediatr. 2023;11:1192021. https:\/\/doi.org\/10.3389\/fped.2023.1192021.","journal-title":"Front Pediatr"},{"issue":"11","key":"1769_CR99","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3390\/cancers17111818","volume":"17","author":"H Goel","year":"2025","unstructured":"Goel H, Pandey AK, Kumar R, Kumar R, Ningombam SS. RNA sequencing identifies WT1 overexpression as a predictor of poor outcomes in acute myeloid leukemia. Cancers. 2025;17(11):1818. https:\/\/doi.org\/10.3390\/cancers17111818.","journal-title":"Cancers"},{"issue":"Supplement_1","key":"1769_CR100","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1182\/blood-2019-130121","volume":"134","author":"C Klein","year":"2019","unstructured":"Klein C, Augsberger C, Xu W, Heitm\u00fcller C, Hanisch L, Sam J, et al. Targeting intracellular WT1 in AML utilizing a T cell bispecific antibody construct: augmenting efficacy through combination with lenalidomide. Blood. 2019;134(Supplement_1):4450\u20134450. https:\/\/doi.org\/10.1182\/blood-2019-130121.","journal-title":"Blood"},{"issue":"12","key":"1769_CR101","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/cgt.2009.35","volume":"16","author":"DE Zamora-Avila","year":"2009","unstructured":"Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA, et al. WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16\u2013F10 lung metastases growth. Cancer Gene Ther. 2009;16(12):892\u20139. https:\/\/doi.org\/10.1038\/cgt.2009.35.","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"1769_CR102","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/ncrna9020021","volume":"9","author":"MR Ramos-Gonzalez","year":"2023","unstructured":"Ramos-Gonzalez MR, Vazquez-Garza E, Garcia-Rivas G, Rodriguez-Aguayo C, Chavez-Reyes A. Therapeutic effects of WT1 silencing via respiratory administration of neutral DOPC liposomal-siRNA in a lung metastasis melanoma murine model. Noncoding RNA. 2023;9(2):21. https:\/\/doi.org\/10.3390\/ncrna9020021.","journal-title":"Noncoding RNA"},{"issue":"4","key":"1769_CR103","doi-asserted-by":"publisher","first-page":"165","DOI":"10.36401\/JIPO-20-12","volume":"3","author":"KZ Hein","year":"2020","unstructured":"Hein KZ, Yao S, Fu S. Wilms\u2019 tumor 1 (WT1): the vaccine for cancer. J Immunother Precis Oncol. 2020;3(4):165\u201371. https:\/\/doi.org\/10.36401\/JIPO-20-12.","journal-title":"J Immunother Precis Oncol"},{"key":"1769_CR104","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v10i4.2762","author":"H Sugiyama","year":"2022","unstructured":"Sugiyama H. WT1 cancer vaccine for the treatment and prevention. Med Res Arch. 2022. https:\/\/doi.org\/10.18103\/mra.v10i4.2762.","journal-title":"Med Res Arch."},{"issue":"24","key":"1769_CR105","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1038\/sj.onc.1206597","volume":"22","author":"M Udtha","year":"2003","unstructured":"Udtha M, Lee SJ, Alam R, Coombes K, Huff V. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms\u2019 tumors. Oncogene. 2003;22(24):3821\u20136. https:\/\/doi.org\/10.1038\/sj.onc.1206597.","journal-title":"Oncogene"},{"issue":"17","key":"1769_CR106","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1038\/sj.onc.1207360","volume":"23","author":"FK Rae","year":"2004","unstructured":"Rae FK, Martinez G, Gillinder KR, Smith A, Shooter G, Forrest AR, et al. Analysis of complementary expression profiles following WT1 induction versus repression reveals the cholesterol\/fatty acid synthetic pathways as a possible major target of WT1. Oncogene. 2004;23(17):3067\u201379. https:\/\/doi.org\/10.1038\/sj.onc.1207360.","journal-title":"Oncogene"},{"issue":"1","key":"1769_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3727\/000000006783991953","volume":"13","author":"K Graham","year":"2006","unstructured":"Graham K, Li W, Williams BR, Fraizer G. Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells. Gene Expr. 2006;13(1):1\u201314. https:\/\/doi.org\/10.3727\/000000006783991953.","journal-title":"Gene Expr"},{"issue":"11","key":"1769_CR108","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1097\/01.asn.0000143474.91362.c4","volume":"15","author":"G Guo","year":"2004","unstructured":"Guo G, Morrison DJ, Licht JD, Quaggin SE. WT1 activates a glomerular-specific enhancer identified from the human nephrin gene. J Am Soc Nephrol. 2004;15(11):2851\u20136. https:\/\/doi.org\/10.1097\/01.asn.0000143474.91362.c4.","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"1769_CR109","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1101\/gad.346405","volume":"19","author":"N Wagner","year":"2005","unstructured":"Wagner N, Wagner KD, Theres H, Englert C, Schedl A, Scholz H. Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms\u2019 tumor transcription factor Wt1. Genes Dev. 2005;19(21):2631\u201342. https:\/\/doi.org\/10.1101\/gad.346405.","journal-title":"Genes Dev"},{"issue":"5","key":"1769_CR110","first-page":"1167","volume":"8","author":"Y Miyoshi","year":"2002","unstructured":"Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms\u2019 tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res. 2002;8(5):1167\u201371.","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"1769_CR111","doi-asserted-by":"publisher","first-page":"e1314","DOI":"10.1200\/JCO.2024.42.16_suppl.e1314","volume":"42","author":"T Zhao","year":"2024","unstructured":"Zhao T, Zhou Y, Wu X, Peng Z, Gao P, Sun N, et al. Effect of transcription factor WT1 on triple-negative breast cancer metastasis through PFKFB4-mediated glycolysis. J Clin Oncol. 2024;42(16_suppl):e1314. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e1314.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1769_CR112","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.7150\/ijbs.39958","volume":"16","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Yan WT, Yang ZY, Li YL, Tan XN, Jiang J, et al. The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism. Int J Biol Sci. 2020;16(8):1474\u201380. https:\/\/doi.org\/10.7150\/ijbs.39958.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"1769_CR113","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1677\/jme.1.01761","volume":"35","author":"N Reizner","year":"2005","unstructured":"Reizner N, Maor S, Sarfstein R, Abramovitch S, Welshons WV, Curran EM, et al. The WT1 Wilms\u2019 tumor suppressor gene product interacts with estrogen receptor-\u03b1 and regulates IGF-I receptor gene transcription in breast cancer cells. J Mol Endocrinol. 2005;35(1):135\u201344. https:\/\/doi.org\/10.1677\/jme.1.01761.","journal-title":"J Mol Endocrinol"},{"issue":"3","key":"1769_CR114","first-page":"1333","volume":"34","author":"T Nasomyon","year":"2014","unstructured":"Nasomyon T, Samphao S, Sangkhathat S, Mahattanobon S, Graidist P. Correlation of Wilms\u2019 tumor 1 isoforms with HER2 and ER-\u03b1 and its oncogenic role in breast cancer. Anticancer Res. 2014;34(3):1333\u201342.","journal-title":"Anticancer Res"},{"key":"1769_CR115","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.gene.2017.03.037","volume":"619","author":"M M\u00fcller","year":"2017","unstructured":"M\u00fcller M, Persson AB, Krueger K, Kirschner KM, Scholz H. The Wilms tumor protein WT1 stimulates transcription of the gene encoding insulin-like growth factor binding protein 5 (IGFBP5). Gene. 2017;619:21\u20139. https:\/\/doi.org\/10.1016\/j.gene.2017.03.037.","journal-title":"Gene"},{"issue":"1\u20132","key":"1769_CR116","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.bbrc.2017.10.043","volume":"494","author":"R Bissanum","year":"2017","unstructured":"Bissanum R, Lirdprapamongkol K, Svasti J, Navakanitworakul R, Kanokwiroon K. The role of WT1 isoforms in vasculogenic mimicry and metastatic potential of human triple negative breast cancer cells. Biochem Biophys Res Commun. 2017;494(1\u20132):256\u201362. https:\/\/doi.org\/10.1016\/j.bbrc.2017.10.043.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1769_CR117","doi-asserted-by":"publisher","first-page":"e57829","DOI":"10.1371\/journal.pone.0057829","volume":"8","author":"M Takeichi","year":"2013","unstructured":"Takeichi M, Nimura K, Mori M, Nakagami H, Kaneda Y. The transcription factors Tbx18 and Wt1 control the epicardial epithelial-mesenchymal transition through bi-directional regulation of Slug in murine primary epicardial cells. PLoS ONE. 2013;8(2):e57829. https:\/\/doi.org\/10.1371\/journal.pone.0057829.","journal-title":"PLoS ONE"},{"key":"1769_CR118","doi-asserted-by":"publisher","first-page":"45255","DOI":"10.1038\/srep45255","volume":"7","author":"M Artibani","year":"2017","unstructured":"Artibani M, Sims A, Slight J, Aitken S, Thornburn A, Muir M, et al. WT1 expression in breast cancer disrupts the epithelial\/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel. Sci Rep. 2017;7:45255. https:\/\/doi.org\/10.1038\/srep45255.","journal-title":"Sci Rep"},{"issue":"1","key":"1769_CR119","doi-asserted-by":"publisher","first-page":"2254557","DOI":"10.1080\/16078454.2023.2254557","volume":"28","author":"J Wu","year":"2023","unstructured":"Wu J, Yan H, Xiang C. Wilms\u2019 tumor gene 1 in hematological malignancies: friend or foe? Hematology. 2023;28(1):2254557. https:\/\/doi.org\/10.1080\/16078454.2023.2254557.","journal-title":"Hematology"},{"issue":"13","key":"1769_CR120","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.3390\/cancers15133491","volume":"15","author":"N Niktoreh","year":"2023","unstructured":"Niktoreh N, Weber L, Walter C, Karimifard M, Hoffmeister LM, Breiter H, et al. Understanding WT1 alterations and expression profiles in hematological malignancies. Cancers (Basel). 2023;15(13):3491. https:\/\/doi.org\/10.3390\/cancers15133491.","journal-title":"Cancers (Basel)"},{"issue":"Suppl 1","key":"1769_CR121","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1182\/blood-2022-166323","volume":"140","author":"X Pan","year":"2022","unstructured":"Pan X, Mengge G, Wang K, Wang Y, Kong J, Sun Y, et al. Prognostic impact of WT1 mutation on AML of different risk groups based on 2022 European Leukemianet (ELN) risk classification. Blood. 2022;140(Suppl 1):3216\u20137. https:\/\/doi.org\/10.1182\/blood-2022-166323.","journal-title":"Blood"},{"issue":"7","key":"1769_CR122","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3390\/jcm11071873","volume":"11","author":"D Koczkodaj","year":"2022","unstructured":"Koczkodaj D, Zmorzyoski S, Grygalewicz B, Pieokowska-Grela B, Styk W, Popek-Marciniec S, et al. WT1 gene mutations, rs16754 variant, and WT1 overexpression as prognostic factors in acute myeloid leukemia patients. J Clin Med. 2022;11(7):1873. https:\/\/doi.org\/10.3390\/jcm11071873.","journal-title":"J Clin Med"},{"issue":"8","key":"1769_CR123","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood.2022016411","volume":"141","author":"M Ghalandary","year":"2023","unstructured":"Ghalandary M, Gao Y, Amend D, Kutkaite G, Vick B, Spiekermann K, et al. WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice. Blood. 2023;141(8):955\u201360. https:\/\/doi.org\/10.1182\/blood.2022016411.","journal-title":"Blood"},{"issue":"4","key":"1769_CR124","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1080\/10428194.2023.2185086","volume":"64","author":"D Pan","year":"2023","unstructured":"Pan D, Zhao W, Jiang Q, et al. Wilms\u2019 tumor 1 expression combined with genetic mutations for prognostic assessment in MDS. Leuk Lymphoma. 2023;64(4):856\u201364. https:\/\/doi.org\/10.1080\/10428194.2023.2185086.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"1769_CR125","doi-asserted-by":"publisher","first-page":"e68837","DOI":"10.1371\/journal.pone.0068837","volume":"8","author":"C Xu","year":"2013","unstructured":"Xu C, Wu C, Xia Y, Zhong Z, Liu X, Xu J, et al. WT1 promotes cell proliferation in non-small cell lung cancer cell lines through up-regulating cyclin D1 and p-pRb in vitro and in vivo. PLoS ONE. 2013;8(8):e68837. https:\/\/doi.org\/10.1371\/journal.pone.0068837.","journal-title":"PLoS ONE"},{"issue":"3","key":"1769_CR126","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ygyno.2015.12.018","volume":"140","author":"ET Taube","year":"2016","unstructured":"Taube ET, Denkert C, Sehouli J, et al. Wilms tumor protein 1 (WT1)\u2014not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. Gynecol Oncol. 2016;140(3):494\u2013502. https:\/\/doi.org\/10.1016\/j.ygyno.2015.12.018.","journal-title":"Gynecol Oncol"},{"issue":"20","key":"1769_CR127","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1080\/15384101.2020.1817666","volume":"19","author":"Y Han","year":"2020","unstructured":"Han Y, Song C, Zhang T, et al. Wilms\u2019 tumor 1 (WT1) promotes ovarian cancer progression by regulating E-cadherin and ERK1\/2 signaling. Cell Cycle. 2020;19(20):2662\u201375. https:\/\/doi.org\/10.1080\/15384101.2020.1817666.","journal-title":"Cell Cycle"},{"issue":"6","key":"1769_CR128","doi-asserted-by":"publisher","first-page":"e004409","DOI":"10.1136\/jitc-2021-004409","volume":"10","author":"RA Van Amerongen","year":"2022","unstructured":"Van Amerongen RA, Hagedoorn RS, Remst DFG, Assendelft DC, van der Steen DM, Wouters A, et al. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma. J Immunother Cancer. 2022;10(6):e004409. https:\/\/doi.org\/10.1136\/jitc-2021-004409.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1769_CR129","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1186\/s12885-024-12541-x","volume":"24","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Liu T, Qin L, Wang C, Peng G, Li Z, et al. Screening of potential hub genes involved in kidney Wilms tumor via bioinformatics analysis and experimental validation. BMC Cancer. 2024;24(1):771. https:\/\/doi.org\/10.1186\/s12885-024-12541-x.","journal-title":"BMC Cancer"},{"issue":"13","key":"1769_CR130","doi-asserted-by":"publisher","first-page":"dev190211","DOI":"10.1242\/dev.190211","volume":"147","author":"TD Treger","year":"2020","unstructured":"Treger TD, et al. Stromal \u03b2-catenin activation impacts nephron progenitor differentiation in the developing kidney and may contribute to Wilms tumor. Development. 2020;147(13):dev190211. https:\/\/doi.org\/10.1242\/dev.190211.","journal-title":"Development"},{"issue":"1","key":"1769_CR131","doi-asserted-by":"publisher","first-page":"e0270380","DOI":"10.1371\/journal.pone.0270380","volume":"18","author":"B Royer-Pokora","year":"2023","unstructured":"Royer-Pokora B, Wruck W, Adjaye J, Beier M. Gene expression studies of WT1 mutant Wilms tumor cell lines in the framework of published kidney development data reveals their early kidney stem cell origin. PLoS ONE. 2023;18(1):e0270380. https:\/\/doi.org\/10.1371\/journal.pone.0270380.","journal-title":"PLoS ONE"},{"issue":"8","key":"1769_CR132","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s43018-023-00609-0","volume":"4","author":"A Rialdi","year":"2023","unstructured":"Rialdi A, Duffy M, Scopton AP, et al. WNTinib is a multi-kinase inhibitor with specificity against \u03b2-catenin mutant hepatocellular carcinoma. Nat Cancer. 2023;4(8):1157\u201375. https:\/\/doi.org\/10.1038\/s43018-023-00609-0.","journal-title":"Nat Cancer"},{"key":"1769_CR133","doi-asserted-by":"publisher","first-page":"1032148","DOI":"10.3389\/fonc.2024.1032148","volume":"14","author":"H Gao","year":"2024","unstructured":"Gao H, et al. Emerging role of WT1 in cancer: a therapeutic target for solid tumors. Front Oncol. 2024;14:1032148. https:\/\/doi.org\/10.3389\/fonc.2024.1032148.","journal-title":"Front Oncol"},{"issue":"9","key":"1769_CR134","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3390\/diagnostics10090637","volume":"10","author":"G Angelico","year":"2020","unstructured":"Angelico G, Santoro A, Straccia P, et al. Diagnostic and prognostic role of WT1 immunohistochemical expression in uterine carcinoma: a systematic review and meta-analysis across all endometrial carcinoma histotypes. Diagnostics. 2020;10(9):637. https:\/\/doi.org\/10.3390\/diagnostics10090637.","journal-title":"Diagnostics"},{"key":"1769_CR135","doi-asserted-by":"publisher","first-page":"100918","DOI":"10.1016\/j.gore.2021.100918","volume":"39","author":"J McEachron","year":"2021","unstructured":"McEachron J, Baqir AW, Zhou N, et al. Evaluation of the incidence and clinical significance of WT-1 expression in uterine serous carcinoma. Gynecol Oncol Rep. 2021;39:100918. https:\/\/doi.org\/10.1016\/j.gore.2021.100918.","journal-title":"Gynecol Oncol Rep"},{"issue":"2","key":"1769_CR136","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.3892\/ol.2018.8961","volume":"16","author":"T Kanai","year":"2018","unstructured":"Kanai T, Ito Z, Oji Y, et al. Prognostic significance of Wilms\u2019 tumor 1 expression in patients with pancreatic ductal adenocarcinoma. Oncol Lett. 2018;16(2):2682\u201392. https:\/\/doi.org\/10.3892\/ol.2018.8961.","journal-title":"Oncol Lett"},{"key":"1769_CR137","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.1038\/srep08924","volume":"5","author":"XW Qi","year":"2015","unstructured":"Qi XW, Zhang F, Wu H, et al. Wilms\u2019 tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep. 2015;5:8924. https:\/\/doi.org\/10.1038\/srep08924.","journal-title":"Sci Rep"},{"issue":"12","key":"1769_CR138","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.1080\/21645515.2021.2003645","volume":"17","author":"S Ota","year":"2021","unstructured":"Ota S, et al. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and\/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy. Hum Vaccin Immunother. 2021;17(12):5563\u201372. https:\/\/doi.org\/10.1080\/21645515.2021.2003645.","journal-title":"Hum Vaccin Immunother"},{"key":"1769_CR139","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1477-7819-12-214","volume":"12","author":"A Kim","year":"2014","unstructured":"Kim A, Park EY, Kim K, et al. Prognostic significance of WT1 expression in soft tissue sarcoma. World J Surg Oncol. 2014;12:214. https:\/\/doi.org\/10.1186\/1477-7819-12-214.","journal-title":"World J Surg Oncol"},{"issue":"4","key":"1769_CR140","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2176\/nmc.47.165","volume":"47","author":"T Hashiba","year":"2007","unstructured":"Hashiba T, Izumoto S, Kagawa N, et al. Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med Chir (Tokyo). 2007;47(4):165\u201370. https:\/\/doi.org\/10.2176\/nmc.47.165.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"3","key":"1769_CR141","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/ijc.IJC_51_18","volume":"56","author":"A Manocha","year":"2019","unstructured":"Manocha A, Jain S. WT1 in astrocytomas: comprehensive evaluation of immunohistochemical expression and its potential utility in different histological grades. Indian J Cancer. 2019;56(3):197\u2013201. https:\/\/doi.org\/10.4103\/ijc.IJC_51_18.","journal-title":"Indian J Cancer"},{"key":"1769_CR142","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/2277-9175.108772","volume":"2","author":"P Mahzouni","year":"2013","unstructured":"Mahzouni P, Meghdadi Z. WT1 protein expression in astrocytic tumors and its relationship with cellular proliferation index. Adv Biomed Res. 2013;2:33. https:\/\/doi.org\/10.4103\/2277-9175.108772.","journal-title":"Adv Biomed Res"},{"issue":"5 Suppl","key":"1769_CR143","doi-asserted-by":"publisher","first-page":"PR08","DOI":"10.1158\/1535-7163.PMS-PR08","volume":"12","author":"R Chen","year":"2013","unstructured":"Chen R, Simpson DR, Zheng Y, Vaka D, Vicen ST, Sweet-Cordero A. Abstract PR08: Identifying effectors of WT1 that regulate KRAS-induced senescence and chemoresistance in non-small cell lung cancer. Mol Cancer Ther. 2013;12(5 Suppl):PR08. https:\/\/doi.org\/10.1158\/1535-7163.PMS-PR08.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1769_CR144","doi-asserted-by":"publisher","first-page":"e28278","DOI":"10.1016\/j.heliyon.2024.e28278","volume":"10","author":"D Xu","year":"2024","unstructured":"Xu D, Chen X, Wu M, Bi J, Xue H, Chen H. Identification of cellular senescence-associated genes as new biomarkers for predicting the prognosis and immunotherapy response of non-small cell lung cancer and construction of a prognostic model. Heliyon. 2024;10(7):e28278. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28278.","journal-title":"Heliyon"},{"issue":"9","key":"1769_CR145","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1158\/0008-5472.CAN-23-3334","volume":"84","author":"JW Magrath","year":"2024","unstructured":"Magrath JW, Sampath SS, Flinchum DA, Hartono AB, Goldberg IN, Boehling JR, et al. Comprehensive transcriptomic analysis of EWSR1::WT1 targets identifies CDK4\/6 inhibitors as an effective therapy for desmoplastic small round cell tumors. Cancer Res. 2024;84(9):1426\u201342. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-3334.","journal-title":"Cancer Res"},{"key":"1769_CR146","doi-asserted-by":"publisher","first-page":"1442488","DOI":"10.3389\/fcell.2024.1442488","volume":"12","author":"JW Magrath","year":"2024","unstructured":"Magrath JW, Espinosa-Cotton M, Flinchum DA, Sampath SS, Cheung NK, Lee SB. Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics. Front Cell Dev Biol. 2024;12:1442488. https:\/\/doi.org\/10.3389\/fcell.2024.1442488.","journal-title":"Front Cell Dev Biol"},{"issue":"Suppl 2","key":"1769_CR147","doi-asserted-by":"publisher","first-page":"S1032S1061","DOI":"10.1016\/S0923-7534(23)01925-7","volume":"34","author":"M Renner","year":"2023","unstructured":"Renner M, Ole\u015b M, Paramasivam N, Schneider A, Heilig CE, Modugno C, et al. 1936P - Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling. Ann Oncol. 2023;34(Suppl 2):S1032S1061. https:\/\/doi.org\/10.1016\/S0923-7534(23)01925-7.","journal-title":"Ann Oncol"},{"issue":"3","key":"1769_CR148","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12185-024-03795-z","volume":"120","author":"S Arai","year":"2024","unstructured":"Arai S, Tachibana T, Izumi A, et al. WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Int J Hematol. 2024;120(3):337\u201346. https:\/\/doi.org\/10.1007\/s12185-024-03795-z.","journal-title":"Int J Hematol"},{"issue":"6","key":"1769_CR149","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/17474086.2017.1326811","volume":"10","author":"B Tomlinson","year":"2017","unstructured":"Tomlinson B, Lazarus HM. Enhancing acute myeloid leukemia therapy\u2014monitoring response using residual disease testing as a guide to therapeutic decision-making. Expert Rev Hematol. 2017;10(6):563\u201374. https:\/\/doi.org\/10.1080\/17474086.2017.1326811.","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"1769_CR150","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, B\u00e9n\u00e9 MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party. Blood. 2018;131(12):1275\u201391. https:\/\/doi.org\/10.1182\/blood-2017-09-801498.","journal-title":"Blood"},{"issue":"4","key":"1769_CR151","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10147-024-02480-9","volume":"29","author":"H Sato","year":"2024","unstructured":"Sato H, Kobayashi T, Kameoka Y, et al. Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy. Int J Clin Oncol. 2024;29(4):481\u201392. https:\/\/doi.org\/10.1007\/s10147-024-02480-9.","journal-title":"Int J Clin Oncol"},{"key":"1769_CR152","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.exphem.2018.02.001","volume":"61","author":"H Li","year":"2018","unstructured":"Li H, Xing C, Zhou B, Ye H, Feng J, Wu J, et al. A regulatory circuitry between miR-193a\/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. Exp Hematol. 2018;61:59-68.e5. https:\/\/doi.org\/10.1016\/j.exphem.2018.02.001.","journal-title":"Exp Hematol"},{"issue":"1","key":"1769_CR153","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbmt.2017.09.001","volume":"24","author":"JF Nomded\u00e9u","year":"2018","unstructured":"Nomded\u00e9u JF, Esquirol A, Carricondo M, et al. Bone marrow WT1 levels in allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplasia: clinically relevant time points and 100 copies threshold value. Biol Blood Marrow Transplant. 2018;24(1):55\u201363. https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.001.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"1769_CR154","first-page":"151","volume":"10","author":"H Goel","year":"2020","unstructured":"Goel H, Rahul E, Gupta AK, et al. Molecular update on biology of Wilms Tumor 1 gene and its applications in acute myeloid leukemia. Am J Blood Res. 2020;10(5):151\u201360.","journal-title":"Am J Blood Res"},{"issue":"22","key":"1769_CR155","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1182\/blood.V114.22.4488.4488","volume":"114","author":"S Messina","year":"2009","unstructured":"Messina S, Tresoldi C, Stanghellini MTL, Crotta A, et al. WT1 transcripts is a powerful leukemia marker to predict early relapse after allogeneic haematopoietic stem cell transplantation. Blood. 2009;114(22):4488. https:\/\/doi.org\/10.1182\/blood.V114.22.4488.4488.","journal-title":"Blood"},{"key":"1769_CR156","doi-asserted-by":"publisher","first-page":"117693512210760","DOI":"10.1177\/11769351221076062","volume":"21","author":"T Hirahata","year":"2022","unstructured":"Hirahata T, Ul Quraish R, Quraish AU, Ul Quraish S, Naz M, Razzaq MA. Liquid biopsy: a distinctive approach to the diagnosis and prognosis of cancer. Cancer Inform. 2022;21:11769351221076062. https:\/\/doi.org\/10.1177\/11769351221076062.","journal-title":"Cancer Inform"},{"issue":"31","key":"1769_CR157","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","volume":"27","author":"D Cilloni","year":"2009","unstructured":"Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195\u2013201.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1769_CR158","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1182\/bloodadvances.2021004322","volume":"5","author":"J Lambert","year":"2021","unstructured":"Lambert J, Thomas X, Marceau-Renaut A, Micol JB, Renneville A, et al. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. Blood Adv. 2021;5(23):5258\u201368. https:\/\/doi.org\/10.1182\/bloodadvances.2021004322.","journal-title":"Blood Adv"},{"issue":"12","key":"1769_CR159","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.3390\/jcm11123306","volume":"11","author":"D Lazzarotto","year":"2022","unstructured":"Lazzarotto D, Candoni A. The role of Wilms\u2019 tumor gene (WT1) expression as a marker of minimal residual disease in acute myeloid leukemia. J Clin Med. 2022;11(12):3306. https:\/\/doi.org\/10.3390\/jcm11123306.","journal-title":"J Clin Med"},{"issue":"1","key":"1769_CR160","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.16362","volume":"188","author":"J Ghannam","year":"2020","unstructured":"Ghannam J, Dillon LW, Hourigan CS. Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia. Br J Haematol. 2020;188(1):77\u201385. https:\/\/doi.org\/10.1111\/bjh.16362.","journal-title":"Br J Haematol"},{"issue":"17","key":"1769_CR161","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.3390\/jcm13175145","volume":"13","author":"S Namdaro\u011flu","year":"2024","unstructured":"Namdaro\u011flu S, Ba\u015fc\u0131 S, Aslan Cand\u0131r B, Yaman S, Yi\u011feno\u011flu TN, Bahsi T, et al. Role of WT1 in measurable residual disease follow-up in the post allogeneic stem cell transplant setting. J Clin Med. 2024;13(17):5145. https:\/\/doi.org\/10.3390\/jcm13175145.","journal-title":"J Clin Med"},{"key":"1769_CR162","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s43042-022-00291-z","volume":"23","author":"HM Donia","year":"2022","unstructured":"Donia HM, Elsweify NM, Farahat NM, Nadwan EA. Wilms tumor 1 gene expression in acute myeloid leukemia: prognostic significance and usefulness in minimal residual disease monitoring\u2014a case\u2013control study. Egypt J Med Hum Genet. 2022;23:109. https:\/\/doi.org\/10.1186\/s43042-022-00291-z.","journal-title":"Egypt J Med Hum Genet"},{"issue":"1","key":"1769_CR163","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1182\/blood-2024-199066","volume":"144","author":"PR Ugale","year":"2024","unstructured":"Ugale PR, Achrekar AR, Biswas S, Joshi S, Terse V, et al. Prognostic significance of Wilms\u2019 tumor 1 gene mutations in acute myeloid leukemia: risk stratification and survival outcomes. Blood. 2024;144(1):1550. https:\/\/doi.org\/10.1182\/blood-2024-199066.","journal-title":"Blood"},{"issue":"2","key":"1769_CR164","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/IGC.0b013e318207cab5","volume":"21","author":"A Coosemans","year":"2011","unstructured":"Coosemans A, Van Calster B, Verbist G, et al. Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma. Int J Gynecol Cancer. 2011;21(2):302\u20138. https:\/\/doi.org\/10.1097\/IGC.0b013e318207cab5.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"1769_CR165","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1007\/s00277-024-05870-1","volume":"103","author":"W Guo","year":"2024","unstructured":"Guo W, Zhang H, Wang M, Zheng Y, Cao Y, et al. WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients. Ann Hematol. 2024;103(8):2827\u201336. https:\/\/doi.org\/10.1007\/s00277-024-05870-1.","journal-title":"Ann Hematol"},{"key":"1769_CR166","doi-asserted-by":"publisher","first-page":"1340909","DOI":"10.3389\/fonc.2024.1340909","volume":"14","author":"S Ahmed","year":"2024","unstructured":"Ahmed S, Elsherif M, Yassin D, et al. Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia. Front Oncol. 2024;14:1340909. https:\/\/doi.org\/10.3389\/fonc.2024.1340909.","journal-title":"Front Oncol"},{"issue":"1","key":"1769_CR167","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/BF02983241","volume":"78","author":"Y Oka","year":"2003","unstructured":"Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol. 2003;78(1):56\u201361. https:\/\/doi.org\/10.1007\/BF02983241.","journal-title":"Int J Hematol"},{"issue":"Suppl 11","key":"1769_CR168","doi-asserted-by":"publisher","first-page":"xi74","DOI":"10.1016\/S0923-7534(20)32149-9","volume":"23","author":"H Sugiyama","year":"2012","unstructured":"Sugiyama H. SY7\u20136-WT1 peptide-based cancer immunotherapy. Ann Oncol. 2012;23(Suppl 11):xi74. https:\/\/doi.org\/10.1016\/S0923-7534(20)32149-9.","journal-title":"Ann Oncol"},{"issue":"7","key":"1769_CR169","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/biomedicines12071455","volume":"12","author":"S Karam","year":"2024","unstructured":"Karam S, Gebreil A, Alksas A, et al. Insights into personalized care strategies for Wilms tumor: a narrative literature review. Biomedicines. 2024;12(7):1455. https:\/\/doi.org\/10.3390\/biomedicines12071455.","journal-title":"Biomedicines"},{"issue":"1","key":"1769_CR170","doi-asserted-by":"publisher","first-page":"2296735","DOI":"10.1080\/21645515.2023.2296735","volume":"20","author":"M Ogasawara","year":"2024","unstructured":"Ogasawara M. Wilms\u2019 tumor 1-targeting cancer vaccine: recent advancements and future perspectives. Hum Vaccin Immunother. 2024;20(1):2296735. https:\/\/doi.org\/10.1080\/21645515.2023.2296735.","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"1769_CR171","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1007\/s00262-023-03432-4","volume":"72","author":"T Naoe","year":"2023","unstructured":"Naoe T, Saito A, Hosono N, et al. Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide. Cancer Immunol Immunother. 2023;72(8):2865\u201371. https:\/\/doi.org\/10.1007\/s00262-023-03432-4.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"1769_CR172","doi-asserted-by":"publisher","first-page":"208","DOI":"10.11412\/jspho.58.208","volume":"58","author":"Y Hashii","year":"2021","unstructured":"Hashii Y. WT1-targeting immunotherapy in children with refractory cancer. Jpn J Pediatr Hematol Oncol. 2021;58(3):208\u201312. https:\/\/doi.org\/10.11412\/jspho.58.208.","journal-title":"Jpn J Pediatr Hematol Oncol"},{"issue":"2","key":"1769_CR173","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00262-018-2274-1","volume":"68","author":"A Tsuboi","year":"2019","unstructured":"Tsuboi A, Hashimoto N, Fujiki F, et al. A phase I clinical study of a cocktail vaccine of Wilms\u2019 tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunol Immunother. 2019;68(2):331\u201340. https:\/\/doi.org\/10.1007\/s00262-018-2274-1.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"1769_CR174","doi-asserted-by":"publisher","first-page":"e56934","DOI":"10.7759\/cureus.56934","volume":"16","author":"KN Gugulothu","year":"2024","unstructured":"Gugulothu KN, Anvesh Sai P, Suraparaju S, Karuturi SP, Pendli G, Kamma RB, et al. WT1 cancer vaccine in advanced pancreatic cancer: a systematic review. Cureus. 2024;16(3):e56934. https:\/\/doi.org\/10.7759\/cureus.56934.","journal-title":"Cureus"},{"issue":"12","key":"1769_CR175","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1007\/s00262-022-03202-8","volume":"71","author":"S Kreutmair","year":"2022","unstructured":"Kreutmair S, Pfeifer D, Waterhouse M, et al. First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience. Cancer Immunol Immunother. 2022;71(12):2913\u201328. https:\/\/doi.org\/10.1007\/s00262-022-03202-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"1769_CR176","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s12185-024-03723-1","volume":"119","author":"T Suwabe","year":"2024","unstructured":"Suwabe T, Shibasaki Y, Tamura S, Katagiri T, Fuse K, Ida-Kurasaki T, et al. Decade-long WT1-specific CTLs induced by WT1 peptide vaccination. Int J Hematol. 2024;119(4):399\u2013406. https:\/\/doi.org\/10.1007\/s12185-024-03723-1.","journal-title":"Int J Hematol"},{"issue":"2","key":"1769_CR177","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1634\/theoncologist.2011-0240","volume":"17","author":"A Van Driessche","year":"2012","unstructured":"Van Driessche A, Berneman ZN, Van Tendeloo VF. Active specific immunotherapy targeting the Wilms\u2019 tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist. 2012;17(2):250\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2011-0240.","journal-title":"Oncologist"},{"key":"1769_CR178","doi-asserted-by":"publisher","first-page":"1374963","DOI":"10.3389\/fonc.2024.1374963","volume":"14","author":"S Bawek","year":"2024","unstructured":"Bawek S, Gurusinghe S, Burwinkel M, Przespolewski A. Updates in novel immunotherapeutic strategies for relapsed\/refractory AML. Front Oncol. 2024;14:1374963. https:\/\/doi.org\/10.3389\/fonc.2024.1374963.","journal-title":"Front Oncol"},{"issue":"2 Suppl","key":"1769_CR179","doi-asserted-by":"publisher","first-page":"B137","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR18-B137","volume":"7","author":"M Versteven","year":"2019","unstructured":"Versteven M, Damoiseaux D, Campillo-Davo D, Van Acker H. Abstract B137: Preclinical evaluation of a Wilms\u2019 tumor protein 1-targeted interleukin-15 dendritic cell vaccine: T-cell activity and batch production. Cancer Immunol Res. 2019;7(2 Suppl):B137. https:\/\/doi.org\/10.1158\/2326-6074.CRICIMTEATIAACR18-B137.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1769_CR180","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13063-019-3332-5","volume":"20","author":"M Katsuda","year":"2019","unstructured":"Katsuda M, Miyazawa M, Ojima T, Hagiwara S, Takahashi R, Yamashita K, et al. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy. Trials. 2019;20(1):242. https:\/\/doi.org\/10.1186\/s13063-019-3332-5.","journal-title":"Trials"},{"issue":"5","key":"1769_CR181","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3390\/cancers15051458","volume":"15","author":"BL Manning-Geist","year":"2023","unstructured":"Manning-Geist BL, Gnjatic S, Aghajanian C, Levine DA, Iasonos A, Sabbatini PJ, et al. Phase I study of a multivalent WT1 peptide vaccine (Galinpepimut-S) in combination with nivolumab in patients with WT1-expressing ovarian cancer in second or third remission. Cancers (Basel). 2023;15(5):1458. https:\/\/doi.org\/10.3390\/cancers15051458.","journal-title":"Cancers (Basel)"},{"issue":"Suppl 2","key":"1769_CR182","doi-asserted-by":"publisher","first-page":"ii23","DOI":"10.1093\/annonc\/mdv093.4","volume":"26","author":"M Takahashi","year":"2015","unstructured":"Takahashi M. Long-term molecular remission with an increase of WT1-specific CTLs after cessation of WT1 peptide vaccination in a patient with CML. Ann Oncol. 2015;26(Suppl 2):ii23. https:\/\/doi.org\/10.1093\/annonc\/mdv093.4.","journal-title":"Ann Oncol"},{"issue":"6","key":"1769_CR183","first-page":"2263","volume":"32","author":"S Ohno","year":"2012","unstructured":"Ohno S, Okuyama R, Aruga A, Sugiyama H, Yamamoto M. Phase I trial of Wilms\u2019 tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anticancer Res. 2012;32(6):2263\u20139.","journal-title":"Anticancer Res"},{"issue":"2","key":"1769_CR184","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00262-010-0929-7","volume":"60","author":"J Kuball","year":"2011","unstructured":"Kuball J, de Boer K, Wagner E, Wattad M, Antunes E, Weeratna RD, et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with Montanide ISA51 and CpG7909. Cancer Immunol Immunother. 2011;60(2):161\u201371. https:\/\/doi.org\/10.1007\/s00262-010-0929-7.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1769_CR185","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-022-03214-4","volume":"72","author":"N Nakagawa","year":"2023","unstructured":"Nakagawa N, Hashii Y, Kayama H, Okumura R, Nakajima H, Minagawa H, et al. An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia. Cancer Immunol Immunother. 2023;72(1):39\u201353. https:\/\/doi.org\/10.1007\/s00262-022-03214-4.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1769_CR186","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-023-10547-5","volume":"23","author":"H Minagawa","year":"2023","unstructured":"Minagawa H, Hashii Y, Nakajima H, Fujiki F, Morimoto S, Nakata J, et al. Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia. BMC Cancer. 2023;23(1):167. https:\/\/doi.org\/10.1186\/s12885-023-10547-5.","journal-title":"BMC Cancer"},{"issue":"2","key":"1769_CR187","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3390\/ijms24021501","volume":"24","author":"SY Cho","year":"2023","unstructured":"Cho SY, Jeong SM, Jeon YJ, Yang S, Hwang JE, Lim SH, et al. WT1 pulsed human CD141+ dendritic cell vaccine has high potential in solid tumor-targeted immunotherapy. Int J Mol Sci. 2023;24(2):1501. https:\/\/doi.org\/10.3390\/ijms24021501.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1769_CR188","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/2326-6066.CIR-17-0386","volume":"6","author":"S Nishida","year":"2018","unstructured":"Nishida S, Ishikawa T, Egawa S, Shimizu S, Takano S, Aoki T, et al. Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: a phase II randomized study. Cancer Immunol Res. 2018;6(3):320\u201331. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0386.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"1769_CR189","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-017-4130-y","volume":"162","author":"M Higgins","year":"2017","unstructured":"Higgins M, Curigliano G, Dieras V, Letarte N, Sahmoud T, Humbert M, et al. Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1positive stage II\/III breast cancer: a randomized phase I study. Breast Cancer Res Treat. 2017;162(3):479\u201388. https:\/\/doi.org\/10.1007\/s10549-017-4130-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1769_CR190","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ymthe.2017.01.022","volume":"25","author":"JN Walters","year":"2017","unstructured":"Walters JN, Ferraro B, Duperret EK, Clark A, Espinosa DA, Krasnow NA, et al. A novel DNA vaccine platform enhances neo-antigen-like T cell responses against WT1 to break tolerance and induce anti-tumor immunity. Mol Ther. 2017;25(4):976\u201388. https:\/\/doi.org\/10.1016\/j.ymthe.2017.01.022.","journal-title":"Mol Ther"},{"issue":"1","key":"1769_CR191","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13073-024-01388-3","volume":"16","author":"X Zhang","year":"2024","unstructured":"Zhang X, Goedegebuure SP, Chen MY, Abbott KL, Hartman ZC, Lin JR, et al. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med. 2024;16(1):131. https:\/\/doi.org\/10.1186\/s13073-024-01388-3.","journal-title":"Genome Med"},{"issue":"6 Suppl","key":"1769_CR192","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1158\/1538-7445.AM2024-6705","volume":"84","author":"S Gao","year":"2024","unstructured":"Gao S, Yang L, Du J, Jiang W, Fang L. Abstract 6705: a novel tri-specific T cell engager targeting the intracellular oncoprotein WT1. Cancer Res. 2024;84(6 Suppl):6705. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-6705.","journal-title":"Cancer Res"},{"key":"1769_CR193","unstructured":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd, CtM Biotech (Shanghai) Co., Ltd. Biocytogen and CtM Bio achieve milestone progress in co-developing a TCR-mimic antibody-based multi-specific T cell engager targeting WT1\/HLA-A02 [Internet]. Beijing and Shanghai (China): Biocytogen; 2023 Dec 27 [cited 2025 Jun 27]. Available from: https:\/\/www.biocytogen.com\/news\/ctm-wt1-milestone"},{"issue":"21","key":"1769_CR194","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1182\/blood-2014-01-549022","volume":"123","author":"L Dubrovsky","year":"2014","unstructured":"Dubrovsky L, Pankov D, Brea EJ, Malavasi F, Lenz HJ, Junghans RP, et al. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood. 2014;123(21):3296\u2013304. https:\/\/doi.org\/10.1182\/blood-2014-01-549022.","journal-title":"Blood"},{"issue":"16","key":"1769_CR195","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.3390\/ijms20163912","volume":"20","author":"Y Shen","year":"2019","unstructured":"Shen Y, Li YM, Zhou JJ, Lu H, Wang F, Zhang Y, et al. The antitumor activity of TCR-mimic antibody-drug conjugates (TCRm-ADCs) targeting the intracellular Wilms tumor 1 (WT1) oncoprotein. Int J Mol Sci. 2019;20(16):3912. https:\/\/doi.org\/10.3390\/ijms20163912.","journal-title":"Int J Mol Sci"},{"key":"1769_CR196","doi-asserted-by":"publisher","unstructured":"Augsberger C, H\u00e4nel G, Xu W, Gans S, Br\u00e4utigam J, Vogel W, et al. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood. 2021 Dec 23;138(25):2655\u201369. Correction in: Blood. 2022 Mar 31; 139(13):2086\u20137. https:\/\/doi.org\/10.1182\/blood.2022015672.","DOI":"10.1182\/blood.2022015672"},{"issue":"11","key":"1769_CR197","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","volume":"72","author":"SS Mun","year":"2023","unstructured":"Mun SS, Meyerberg J, Peraro L, Benmebarek MR, Touzot M, Sebbagh R, et al. Dual targeting ovarian cancer by MUC16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer Immunol Immunother. 2023;72(11):3773\u201386. https:\/\/doi.org\/10.1007\/s00262-023-03529-w.","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"1769_CR198","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12935-018-0720-y","volume":"3","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Li Y. T cell receptor-engineered T cells for leukemia immunotherapy. Cancer Cell Int. 2019;3(19):2. https:\/\/doi.org\/10.1186\/s12935-018-0720-y.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1769_CR199","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00277-024-05919-1","volume":"104","author":"S Gielis","year":"2025","unstructured":"Gielis S, Flumens D, van der Heijden S, van Acker H, Peeters M, Willems E, et al. Analysis of Wilms\u2019 tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed. Ann Hematol. 2025;104(1):317\u201333. https:\/\/doi.org\/10.1007\/s00277-024-05919-1.","journal-title":"Ann Hematol"},{"issue":"18","key":"1769_CR200","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","volume":"130","author":"I Tawara","year":"2017","unstructured":"Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Chiba S, et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 2017;130(18):1985\u201394. https:\/\/doi.org\/10.1182\/blood-2017-06-791202.","journal-title":"Blood"},{"issue":"12","key":"1769_CR201","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/intimm\/dxab091","volume":"33","author":"H Kawamoto","year":"2021","unstructured":"Kawamoto H, Masuda K, Nagano S. Regeneration of antigen-specific T cells by using induced pluripotent stem cell (iPSC) technology. Int Immunol. 2021;33(12):827\u201333. https:\/\/doi.org\/10.1093\/intimm\/dxab091.","journal-title":"Int Immunol"},{"key":"1769_CR202","doi-asserted-by":"publisher","first-page":"eabg8027","DOI":"10.1126\/scitranslmed.abg8027","volume":"14","author":"E Ruggiero","year":"2022","unstructured":"Ruggiero E, Carnevale E, Prodeus A, Magnani ZI, Camisa B, Merelli I, et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci Transl Med. 2022;14:eabg8027. https:\/\/doi.org\/10.1126\/scitranslmed.abg8027.","journal-title":"Sci Transl Med."},{"issue":"34","key":"1769_CR203","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.2174\/0929867325666180403141554","volume":"26","author":"S Naghizadeh","year":"2019","unstructured":"Naghizadeh S, Mansoori B, Mohammadi A, Sakhinia E, Baradaran B. Gene silencing strategies in cancer therapy: an update for drug resistance. Curr Med Chem. 2019;26(34):6282\u2013300. https:\/\/doi.org\/10.2174\/0929867325666180403141554.","journal-title":"Curr Med Chem"},{"issue":"8","key":"1769_CR204","doi-asserted-by":"publisher","first-page":"13917","DOI":"10.18632\/oncotarget.14715","volume":"8","author":"AC Graziano","year":"2017","unstructured":"Graziano AC, Cardile V, Avola R, Tomasello L, Battiato C, Giunta E, et al. Wilms\u2019 tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. Oncotarget. 2017;8(8):13917\u201331. https:\/\/doi.org\/10.18632\/oncotarget.14715.","journal-title":"Oncotarget"},{"issue":"3","key":"1769_CR205","first-page":"326","volume":"90","author":"AH Elmaagacli","year":"2005","unstructured":"Elmaagacli AH, Koldehoff M, Peceny R, Trenschel R, Beelen DW, Hallek M, et al. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica. 2005;90(3):326\u201334.","journal-title":"Haematologica"},{"issue":"10","key":"1769_CR206","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1038\/sj.leu.2404878","volume":"21","author":"W Glienke","year":"2007","unstructured":"Glienke W, Maute L, Koehl U, Esser R, Milz E, Bergmann L. Effective treatment of leukemic cell lines with WT1 siRNA. Leukemia. 2007;21(10):2164\u201370. https:\/\/doi.org\/10.1038\/sj.leu.2404878.","journal-title":"Leukemia"},{"issue":"3","key":"1769_CR207","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","volume":"2","author":"PG Maslak","year":"2018","unstructured":"Maslak PG, Dao T, Bernal Y, Smith JS, O\u2019Rourke K, Cooper LJ, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224\u201334. https:\/\/doi.org\/10.1182\/bloodadvances.2017014175.","journal-title":"Blood Adv"},{"issue":"11","key":"1769_CR208","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1038\/mtna.2013.54","volume":"2","author":"D Benteyn","year":"2013","unstructured":"Benteyn D, Anguille S, Van Lint S, Heirman C, Van Overmeire E, Berghen C, et al. Design of an optimized Wilms\u2019 tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo. Mol Ther Nucleic Acids. 2013;2(11):e134. https:\/\/doi.org\/10.1038\/mtna.2013.54.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"1769_CR209","doi-asserted-by":"publisher","first-page":"e077613","DOI":"10.1136\/bmjopen-2023-077613","volume":"14","author":"T Van Genechten","year":"2024","unstructured":"Van Genechten T, De Laere M, Van den Bossche J, Goovaerts T, Peeters M, Van Camp B, et al. Adjuvant Wilms\u2019 tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with highgrade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I\/II clinical trial in Belgium. BMJ Open. 2024;14(3):e077613. https:\/\/doi.org\/10.1136\/bmjopen-2023-077613.","journal-title":"BMJ Open"},{"issue":"11","key":"1769_CR210","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1038\/leu.2015.125","volume":"29","author":"Q Zhao","year":"2015","unstructured":"Zhao Q, Ahmed M, Tassev DV, Savoldo B, Majumder P, Cruz CRY, et al. Affinity maturation of T-cell receptor-like antibodies for Wilms tumour 1 peptide greatly enhances therapeutic potential. Leukemia. 2015;29(11):2238\u201347. https:\/\/doi.org\/10.1038\/leu.2015.125.","journal-title":"Leukemia"},{"issue":"6","key":"1769_CR211","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CMR.0b013e3282efd3ae","volume":"17","author":"DE Zamora-Avila","year":"2007","unstructured":"Zamora-Avila DE, Franco-Molina MA, Trejo-Avila LM, Rodr\u00edguez-Padilla C, Res\u00e9ndez-P\u00e9rez D, Zapata-Benavides P. RNAi silencing of the WT1 gene inhibits cell proliferation and induces apoptosis in the B16F10 murine melanoma cell line. Melanoma Res. 2007;17(6):341\u20138. https:\/\/doi.org\/10.1097\/CMR.0b013e3282efd3ae.","journal-title":"Melanoma Res"},{"issue":"3","key":"1769_CR212","first-page":"701","volume":"32","author":"N Tatsumi","year":"2008","unstructured":"Tatsumi N, Oji Y, Tsuji N, Ohno T, Sugiyama H, Komatsu T, et al. Wilms\u2019 tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. Int J Oncol. 2008;32(3):701\u201311.","journal-title":"Int J Oncol"},{"issue":"2","key":"1769_CR213","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/BF02982573","volume":"76","author":"DM Loeb","year":"2002","unstructured":"Loeb DM, Sukumar S. The role of WT1 in oncogenesis: tumor suppressor or oncogene? Int J Hematol. 2002;76(2):117\u201326. https:\/\/doi.org\/10.1007\/BF02982573.","journal-title":"Int J Hematol"},{"issue":"1","key":"1769_CR214","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13048-023-01124-2","volume":"16","author":"X Wang","year":"2023","unstructured":"Wang X, Zhao J, Zhang Y, He Y, Li G, Chen H, et al. Molecular mechanism of Wilms\u2019 tumor (Wt1) +\/\u2212KTS variants promoting proliferation and migration of ovarian epithelial cells by bioinformatics analysis. J Ovarian Res. 2023;16(1):46. https:\/\/doi.org\/10.1186\/s13048-023-01124-2.","journal-title":"J Ovarian Res"},{"issue":"21","key":"1769_CR215","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1182\/blood.V120.21.2500.250","volume":"120","author":"C Calabrese","year":"2012","unstructured":"Calabrese C, Pica GM, Bracco E, Serra A, D\u2019Amico G, Battaglia M, et al. Detection of an unbalanced ratio between WT1 isoforms in acute myeloid leukemia and its correlation with molecular abnormalities. Blood. 2012;120(21):2500. https:\/\/doi.org\/10.1182\/blood.V120.21.2500.250.","journal-title":"Blood"},{"issue":"2","key":"1769_CR216","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/pbc.22522","volume":"55","author":"Y Hashii","year":"2010","unstructured":"Hashii Y, Sato E, Ohta H, Oka Y, Sugiyama H, Ozono K. WT1 peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer. 2010;55(2):352\u20135. https:\/\/doi.org\/10.1002\/pbc.22522.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"1769_CR217","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00262-02103074-4","volume":"71","author":"T Kiguchi","year":"2022","unstructured":"Kiguchi T, Yamaguchi M, Takezako N, Yamamoto K, Tsujita T, Tanaka J, et al. Efficacy and safety of Wilms\u2019 tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial. Cancer Immunol Immunother. 2022;71(6):1419\u201330. https:\/\/doi.org\/10.1007\/s00262-02103074-4.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1769_CR218","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3892\/ol.2018.8734","volume":"16","author":"T Matsuda","year":"2018","unstructured":"Matsuda T, Takeuchi H, Sakurai T, Komori T, Yoshida K, Mori T, et al. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. Oncol Lett. 2018;16(1):1348\u201356. https:\/\/doi.org\/10.3892\/ol.2018.8734.","journal-title":"Oncol Lett"},{"issue":"4","key":"1769_CR219","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/cas.12621","volume":"106","author":"S Mayanagi","year":"2015","unstructured":"Mayanagi S, Kitago M, Sakurai T, Komori T, Mori T, Saisho S, et al. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci. 2015;106(4):397\u2013406. https:\/\/doi.org\/10.1111\/cas.12621.","journal-title":"Cancer Sci"},{"issue":"5","key":"1769_CR220","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1158\/1535-7163.MCT-18-1105","volume":"18","author":"K Kitagawa","year":"2019","unstructured":"Kitagawa K, Gonoi R, Tatsumi M, Matsushita H, Mori T, Saisho S, et al. Preclinical development of a WT1 oral cancer vaccine using a bacterial vector to treat castration-resistant prostate cancer. Mol Cancer Ther. 2019;18(5):980\u201390. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-1105.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1769_CR221","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/CJI.0000000000000020","volume":"37","author":"S Nishida","year":"2014","unstructured":"Nishida S, Koido S, Takeda Y, Yamamoto S, Komori T, Hashii Y, et al. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother. 2014;37(2):105\u201314. https:\/\/doi.org\/10.1097\/CJI.0000000000000020.","journal-title":"J Immunother"},{"issue":"10","key":"1769_CR222","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3389\/fonc.2020.01188","volume":"24","author":"Y Hashii","year":"2020","unstructured":"Hashii Y, Oka Y, Kagawa N, Komori T, Hashimoto H, Hashimoto Y, et al. Encouraging clinical evolution of a pediatric patient with relapsed diffuse midline glioma who underwent WT1-targeting immunotherapy: a case report and literature review. Front Oncol. 2020;24(10):1188. https:\/\/doi.org\/10.3389\/fonc.2020.01188.","journal-title":"Front Oncol"},{"key":"1769_CR223","doi-asserted-by":"publisher","first-page":"90","DOI":"10.21037\/sci.2016.11.08","volume":"3","author":"N Hosen","year":"2016","unstructured":"Hosen N, Maeda T, Hashii Y, Kawaguchi R, Komori T, Saisho S, et al. Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients. Stem Cell Investig. 2016;3:90. https:\/\/doi.org\/10.21037\/sci.2016.11.08.","journal-title":"Stem Cell Investig"},{"issue":"7","key":"1769_CR224","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/00085472.CAN-11-2957","volume":"72","author":"S Van Lint","year":"2012","unstructured":"Van Lint S, Goyvaerts C, Maenhout S, Heirman C, Van der Bruggen P, Thielemans K, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 2012;72(7):1661\u201371. https:\/\/doi.org\/10.1158\/00085472.CAN-11-2957.","journal-title":"Cancer Res"},{"issue":"1","key":"1769_CR225","doi-asserted-by":"publisher","first-page":"e000329","DOI":"10.1136\/jitc-2019-000329","volume":"8","author":"B De Keersmaecker","year":"2020","unstructured":"De Keersmaecker B, Claerhout S, Carrasco J, Anguille S, Van Lint S, Van den Oord J, et al. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. J Immunother Cancer. 2020;8(1):e000329. https:\/\/doi.org\/10.1136\/jitc-2019-000329.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"1769_CR226","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3390\/pharmaceutics15092305","volume":"15","author":"M Chen","year":"2023","unstructured":"Chen M, Fang X, Du R, Zhang Y, Li Q, Zhao B, et al. A nucleus-targeting WT1 antagonistic peptide encapsulated in polymeric nanomicelles combats refractory chronic myeloid leukemia. Pharmaceutics. 2023;15(9):2305. https:\/\/doi.org\/10.3390\/pharmaceutics15092305.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1769_CR227","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/vaccines11020394","volume":"11","author":"YJ Xie","year":"2023","unstructured":"Xie YJ, Liu WQ, Li D, Hou JC, Coghi PS, Fan XX. Overcoming suppressive tumor microenvironment by vaccines in solid tumor. Vaccines (Basel). 2023;11(2):394. https:\/\/doi.org\/10.3390\/vaccines11020394.","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"1769_CR228","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/med.2019.04.01","volume":"15","author":"M Suzuki","year":"2019","unstructured":"Suzuki M, Hishida T, Asakura K, Asamura H. WT1 peptide-based immunotherapy for refractory thymic epithelial malignancies. Mediastinum. 2019;15(3):12. https:\/\/doi.org\/10.21037\/med.2019.04.01.","journal-title":"Mediastinum"},{"issue":"1","key":"1769_CR229","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-024-03862-8","volume":"74","author":"S Morimoto","year":"2024","unstructured":"Morimoto S, Tanaka Y, Nakata J, Takayama T, Saisho S, Komori T, et al. Spontaneous high clonal expansion of Wilms\u2019 tumor gene 1-specific cytotoxic T-lymphocytes in patients with Wilms\u2019 tumor gene 1-expressing solid tumor. Cancer Immunol Immunother. 2024;74(1):15\u201323. https:\/\/doi.org\/10.1007\/s00262-024-03862-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"1769_CR230","doi-asserted-by":"publisher","first-page":"e0308330","DOI":"10.1371\/journal.pone.0308330","volume":"19","author":"M Ito","year":"2024","unstructured":"Ito M, Koido S, Iwamoto T, Komori T, Saisho S, Kawashima H, et al. Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitors. PLoS ONE. 2024;19(8):e0308330. https:\/\/doi.org\/10.1371\/journal.pone.0308330.","journal-title":"PLoS ONE"},{"issue":"631","key":"1769_CR231","doi-asserted-by":"publisher","first-page":"eabg8070","DOI":"10.1126\/scitranslmed.abg8070","volume":"14","author":"MC Lahman","year":"2022","unstructured":"Lahman MC, Schmitt TM, Paulson KG, Segal NH, Lim M, Spitz FR, et al. Targeting an alternate Wilms\u2019 tumor antigen 1 peptide bypasses immunoproteasome dependency. Sci Transl Med. 2022;14(631):eabg8070. https:\/\/doi.org\/10.1126\/scitranslmed.abg8070.","journal-title":"Sci Transl Med."},{"issue":"1","key":"1769_CR232","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12885-021-08022-0","volume":"21","author":"DX Deng","year":"2021","unstructured":"Deng DX, Wen JJ, Cheng YF, Yang WZ, Li YM, Liu Y, et al. Wilms\u2019 tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. BMC Cancer. 2021;21(1):292. https:\/\/doi.org\/10.1186\/s12885-021-08022-0.","journal-title":"BMC Cancer"},{"issue":"2","key":"1769_CR233","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/sj.leu.2404047","volume":"20","author":"L Boublikova","year":"2006","unstructured":"Boublikova L, Kalinova M, Ryan J, Trka J, Semeradova L, Chroma J, et al. Wilms\u2019 tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia. 2006;20(2):254\u201363. https:\/\/doi.org\/10.1038\/sj.leu.2404047.","journal-title":"Leukemia"},{"issue":"13","key":"1769_CR234","doi-asserted-by":"publisher","first-page":"1297870","DOI":"10.3389\/fonc.2023.1297870","volume":"15","author":"Y Xue","year":"2024","unstructured":"Xue Y, Wang Y, Zhang LP, Chen L, Li J, Zhao J, et al. Prognostic significance of Wilms\u2019 tumor gene 1 expression in children with B-cell precursor acute lymphoblastic leukemia. Front Oncol. 2024;15(13):1297870. https:\/\/doi.org\/10.3389\/fonc.2023.1297870.","journal-title":"Front Oncol"},{"issue":"8","key":"1769_CR235","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-08-2589","volume":"15","author":"T Osada","year":"2009","unstructured":"Osada T, Woo CY, McKinney M, Younes A, Takita H, Yoshimoto M, et al. Induction of Wilms\u2019 tumor protein (WT1)specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Clin Cancer Res. 2009;15(8):2789\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2589.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1769_CR236","doi-asserted-by":"publisher","first-page":"5751","DOI":"10.21873\/anticanres.16082","volume":"42","author":"Y Morishita","year":"2022","unstructured":"Morishita Y, Takenouchi K, Sakashita S, Matsuura K, Hayashi R, Nakatsura T. Immunohistochemical analysis of common cancer antigens in head and neck squamous cell carcinoma. Anticancer Res. 2022;42(12):5751\u201361. https:\/\/doi.org\/10.21873\/anticanres.16082.","journal-title":"Anticancer Res"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01769-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:48:38Z","timestamp":1764917318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01769-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":236,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01769-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This manuscript does not involve the use of animal or human data or tissue; therefore, ethical approval is not required in this section.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"336"}}